Search - tctmd.com

Displaying 21 - 40 of 297

Sort: Relevancy | Date

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

Presentation THT 2025

Back to Normal? Reverse Remodeling of the Left Ventricle

Presenter: Daniel Burkhoff

February 12, 2025

Presentation THT 2025

Let's Cinch It: AccuCinch Case Study

Presenter: Dominick Bufalino

February 12, 2025

Presentation THT 2025

Who are CORCINCH-HF patients?

Presenter: Jacob Abraham

February 12, 2025

Presentation THT 2025

AccuCinch TLVR and the CORCINCH-HF Study

Presenter: Ulrich Jorde

February 12, 2025

Presentation THT 2025

Stem Cell Based Therapies for HFpEF and HFrEF

Presenter: Sunjay Kushal

February 12, 2025

Presentation THT 2025

Controlled Pulmonary Artery Banding for HFrEF (Restore Medical)

Presenter: Sean Pinney

February 12, 2025

Presentation THT 2025

Transcatheter Pulmonary Artery Banding [PAB] for HFrEF: Two Year Follow Up and Invasive Exercise Hemodynamics From the Ongoing First-In-Human Trial

Presenter: Sean Pinney

February 12, 2025

Presentation THT 2025

Interatrial Shunts and the HFrEF - HFpEF Divide: The Differential Effects in RELIEVE-HF Explained?

Presenter: JoAnn Lindenfeld

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Presentation THT 2025

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Presenter: Gregg W. Stone

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Presentation THT 2025

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFrEF Patients

Presenter: NULL

February 11, 2025

Presentation THT 2025

Is There a Difference in the Benefits of AF Ablation in HFrEF vs HFpEF?

Presenter: Andrea Russo

February 11, 2025

News Daily News

NT-proBNP Cutoffs for HFpEF Diagnosis May Need Tweaking

Todd Neale

January 29, 2025

Advertisement

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Back to Normal? Reverse Remodeling of the Left Ventricle

Let's Cinch It: AccuCinch Case Study

Who are CORCINCH-HF patients?

AccuCinch TLVR and the CORCINCH-HF Study

Stem Cell Based Therapies for HFpEF and HFrEF

Controlled Pulmonary Artery Banding for HFrEF (Restore Medical)

Transcatheter Pulmonary Artery Banding [PAB] for HFrEF: Two Year Follow Up and Invasive Exercise Hemodynamics From the Ongoing First-In-Human Trial

Interatrial Shunts and the HFrEF - HFpEF Divide: The Differential Effects in RELIEVE-HF Explained?

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFrEF Patients

Is There a Difference in the Benefits of AF Ablation in HFrEF vs HFpEF?

NT-proBNP Cutoffs for HFpEF Diagnosis May Need Tweaking

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content